Immunohistrochemistry Expression of COX-2 as a Prognostic Factor for Survival in Locally Advanced Cervical Cancer Treated with Concurrent Cisplatin-Radiation Therapy

Authors

  • Jiraporn Setakornnukul

Abstract

Objective: Cervical cancer is a major health problem for women. Concurrent Cisplatin-radiation therapy (CCRT) can improve survival, although result of treatment is still not satisfactory.   Many prognostic factors have been known, but they cannot explain all the results. Cyclooxygenase-2 (COX-2) is one of the molecular factors related to angiogenesis that can lead to more accurate predictive outcome and modification of the treatment in the future.
Methods: Retrospective study to find relationship of COX-2 expression to overall survival (OS), progression free survival (PFS), distant metastasis free survival (DMFS), and loco-regional relapse free survival (LRRFS) of locally advanced cervical cancer in patients who were treated with CCRT at Siriraj Hospital from 2002 to 2007. In this COX-2 IHC study, the interpretations of results were based on both intensity and quantity score.
Results: There were 49 patients included into the study. COX-2 was positive in 36 (73%).    Median f/u time was 22 months.   COX-2 expression was proven to be a significant prognostic factor to predict OS and PFS with HR 19.5 (95% CI 1.1-337.2) and HR 27.1 (95% CI 2.1-355.6) respectively. Total treatment time (>55 days) is the most significant prognostic factor for OS, PFS and DMF.   
Conclusion: Expression of COX-2 positive is a significant prognostic factor to predict worse OS and PFS compared to COX-2 negative group in multivariate analysis. The COX-2 scoring system used in this study was good to predict prognosis.

Keywords: Locally advanced cervical cancer, expression of COX-2, prognosis factor, concurrent chemo-radiotherapy

Downloads

Published

26-11-2014

How to Cite

Setakornnukul, J. (2014). Immunohistrochemistry Expression of COX-2 as a Prognostic Factor for Survival in Locally Advanced Cervical Cancer Treated with Concurrent Cisplatin-Radiation Therapy. Siriraj Medical Journal, 66(5). Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/55278

Issue

Vol. 66 No. 5 (2014): September-October

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.